2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow BMS-986368: new trials by email Literature Review of BMS-986368 trials Research Report on BMS-986368
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease BMS-986368, Placebo - Agitation, Alzheimer Disease | Phase 2 | Recruiting | Celgene | 120 | 2025-06-09 | 2026-10-06 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity BMS-986368, Placebo - Multiple Sclerosis Spasticity | Phase 2 | Recruiting | Celgene | 200 | 2025-06-05 | 2026-10-27 |
Alzheimer Disease (1) · Multiple Sclerosis (1) · Muscle Spasticity (1) · Psychomotor Agitation (1)
Celgene (2)
Australia (2) · United States (2) · Argentina (1) · Canada (1) · China (1) · Czechia (1) · Germany (1) · Poland (1) · Puerto Rico (1)